2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
申请人:Cheng Leifeng
公开号:US20060135523A1
公开(公告)日:2006-06-22
The present invention relates to 2-substituted-5,6-diarylpyrazine compounds and their compositions, processes for their preparation, and their use in the treatment of obesity and psychiatric and neurological disorders.
2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR.
申请人:AstraZeneca AB
公开号:EP1641779A1
公开(公告)日:2006-04-05
[EN] 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR.<br/>[FR] AGENTS THERAPEUTIQUES
申请人:ASTRAZENECA AB
公开号:WO2004111033A1
公开(公告)日:2004-12-23
The present invention relates to 5, 6-diaryl-pyrazine-2-carboxamide and- 2-ester derivatives and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them. The compounds are cannabinoid receptor 1 (CB1) modulators.